首页> 美国卫生研究院文献>Regenerative Biomaterials >Can microfluidics address biomanufacturing challenges in drug/gene/cell therapies?
【2h】

Can microfluidics address biomanufacturing challenges in drug/gene/cell therapies?

机译:微流体技术能否应对药物/基因/细胞疗法中的生物制造挑战?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Translation of any inventions into products requires manufacturing. Development of drug/gene/cell delivery systems will eventually face manufacturing challenges, which require the establishment of standardized processes to produce biologically-relevant products of high quality without incurring prohibitive cost. Microfluidicu technologies present many advantages to improve the quality of drug/gene/cell delivery systems. They also offer the benefits of automation. What remains unclear is whether they can meet the scale-up requirement. In this perspective, we discuss the advantages of microfluidic-assisted synthesis of nanoscale drug/gene delivery systems, formation of microscale drug/cell-encapsulated particles, generation of genetically engineered cells and fabrication of macroscale drug/cell-loaded micro-ano-fibers. We also highlight the scale-up challenges one would face in adopting microfluidic technologies for the manufacturing of these therapeutic delivery systems.
机译:任何发明到产品的转化都需要制造。药物/基因/细胞递送系统的开发最终将面临制造挑战,这需要建立标准化的流程来生产高质量的生物相关产品而又不会产生高昂的成本。微流体技术具有许多优势,可以提高药物/基因/细胞递送系统的质量。它们还提供了自动化的好处。尚不清楚的是它们是否可以满足扩大规模的要求。从这个角度出发,我们讨论了纳米级药物/基因递送系统的微流体辅助合成,微米级药物/细胞包封颗粒的形成,基因工程细胞的产生以及大规模药物/细胞加载的微米/纳米制备的优势。纤维。我们还强调了在采用微流体技术制造这些治疗性输送系统时将面临的规模挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号